Dr Reddy’s Laboratories announced that it has launched Montelukast Sodium Oral Granules, a bioequivalent generic version of Singulair (montelukast sodium) oral granules, in the US market. The drug is used for treating asthma and seasonal allergies. The move follows the approval by the United States Food & Drug Administration (USFDA) of Dr Reddy’s Abbreviated New Drug Application for Montelukast Sodium Oral Granules, a company press release said. The Singulair oral granules brand had US sales of approximately $61 million for the most recent twelve months ending July, according to IMS Health. Dr Reddy’s Montelukast Sodium oral granules in 4 mg are available in unit dosage package of 30.
Dr Reddy’s launches anti-asthma drug
Hyderabad, Sept. 27: